Sanofi India Limited — Investor Meet, 05-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sanofi India's Q2 saw strong domestic sales (+8%), driving total income up 7% to 443.9 Cr. Profit Before Tax (PBT) surged 19% to 112.3 Cr, boosting margins to 27%. While H1 total income and PBT were nearly flat/slightly down, the diabetes business was a key growth driver, up 17% in H1, accelerating above market and boosting public sector accounts by 70%. Strategic transformation focusing on Insulin and partnerships is complete, with optimized operations and AI-enhanced capabilities positioning the company for India's high-growth diabetes market.